Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both
hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary
mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall
objective of the study is to evaluate the efficacy and safety of combining fenofibrate and
simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.